New imaging agents for studying gene expression

用于研究基因表达的新型成像剂

基本信息

  • 批准号:
    7093967
  • 负责人:
  • 金额:
    $ 22.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-01 至 2008-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose to develop F-18 and 1-123 labeled nucleosides as selective substrates of herpes simplex thymidine kinase (HSV1-TK) in conjunction with positron computed tomography (PET). Introduction of HSV1- TK in tumor followed by gancyclovir (GCV) treatment has been successfully tested as a suicide gene therapy for cancer therapy. Labeled nucleosides (such as [1-123/124]FIAU and [F-18JFHBG) selectively targeting the HSV1-TK enzyme are useful as reporter probes for measuring HSV1-tk gene expression in vivo by PET or SPECT imaging. Based on this approach, HSV1-tk gene expression can also be used as a surrogate marker gene for expression of other genes (transgenes) determined by the labeled nucleosides as in vivo imaging probes. The objective of this project is to design, synthesize and characterize a series of novel labeled nucleosides, 2'-deoxyuridine and FIAU analogs (group A and B), as superior imaging agents for measuring in vivo gene expression. Currently, [F-18]FIAU is more effective for imaging HSV1-TK; but the synthesis of this F-18 probe is very long and difficult. [F-18]FHBG is easier to prepare, but only effective for imaging a mutant HSV1-TK(sr39). The purposes of developing these novel nucleosides are: 1) to prepare F-18 radiolabeled group A and B nucleosides 2). to identify improved F-18 nucleoside probes with desired in vivo kinetics for higher target to non-target ratio and a higher selectivity between the human TK vs viral HSV1-TK enzyme and 3) to test the correlation between gene expression and probe-uptake in a doxycycline inducible HSV1-TK expressing cell line. It is likely that the new probes can be selectively phosphorylated by the viral enzyme, as such they may be superior for measuring the concentration of HSV1-TK enzyme levels in the tumor cells. They will have several useful properties: ability to cross the cell membrane and a minimum influence from other metabolic steps of nucleosides and nucleotides. Efforts will be made to select tracers predominantly trapped in the targeted cells by the native HSV1-TK only, and confounding signals from other processes from native hTK1 and hTK2 enzymes are minimized. In conjunction with PET, these new imaging agents may enhance our ability to measure tk gene expression in vivo; thus, they may enhance the probability of developing new gene therapy approaches for various diseases.
描述(由申请人提供):我们建议开发F-18和1-123标记的核苷作为单纯疱疹胸苷激酶(HSV 1-TK)的选择性底物,并结合正电子计算机断层扫描(PET)。在肿瘤中引入HSV 1- TK,随后进行更昔洛韦(GCV)治疗已成功地测试为用于癌症治疗的自杀基因疗法。选择性靶向HSV 1-TK酶的标记核苷(如[1-123/124]FIAU和[F-18] FHBG)可用作报告探针,用于通过PET或SPECT成像测量体内HSV 1-tk基因表达。基于这种方法,HSV 1-tk基因表达也可以用作由标记的核苷作为体内成像探针确定的其他基因(转基因)表达的替代标记基因。本项目的目的是设计、合成和表征一系列新型标记核苷、2 '-脱氧尿苷和FIAU类似物(A组和B组),作为用于测量体内基因表达的上级成像剂。目前,[F-18]FIAU用于HSV 1-TK的成像更有效;但这种F-18探针的合成非常长且困难。[F-18]FHBG更容易制备,但仅对突变型HSV 1-TK(sr 39)成像有效。开发这些新核苷的目的是:1)制备F-18放射性标记的A和B组核苷2)。鉴定具有所需体内动力学的改进的F-18核苷探针,用于更高的靶与非靶比率和人TK与病毒HSV 1-TK酶之间更高的选择性,和3)测试在多西环素诱导的HSV 1-TK表达细胞系中基因表达和探针摄取之间的相关性。很可能新探针可以被病毒酶选择性磷酸化,因此它们对于测量肿瘤细胞中HSV 1-TK酶水平的浓度可能是上级的。它们将具有几个有用的特性:穿过细胞膜的能力以及核苷和核苷酸的其他代谢步骤的最小影响。将努力选择仅通过天然HSV 1-TK主要捕获在靶细胞中的示踪剂,并使来自天然hTK 1和hTK 2酶的其他过程的混杂信号最小化。与PET结合,这些新的显像剂可以提高我们在体内测量tk基因表达的能力;因此,它们可以提高开发用于各种疾病的新基因治疗方法的可能性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hank F Kung其他文献

First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
PSMA 靶向剂 [18F]AlF-P16-093 的首次人体研究:前列腺癌患者的剂量测定和初步评估。
  • DOI:
    10.1007/s00259-024-06596-y
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    9.1
  • 作者:
    Ruiyue Zhao;Miao Ke;Jie Lv;Shaoyu Liu;Yuheng Liu;Jing Zhang;Lifu Xu;Di Gu;Mingzhao Li;Chao Cai;Yong;Guohua Zeng;D. Alexoff;K. Ploessl;Lin Zhu;Hank F Kung;Xinlu Wang
  • 通讯作者:
    Xinlu Wang

Hank F Kung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hank F Kung', 18)}}的其他基金

IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    7781545
  • 财政年份:
    2010
  • 资助金额:
    $ 22.93万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8052716
  • 财政年份:
    2010
  • 资助金额:
    $ 22.93万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8310307
  • 财政年份:
    2010
  • 资助金额:
    $ 22.93万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8255583
  • 财政年份:
    2010
  • 资助金额:
    $ 22.93万
  • 项目类别:
IMAGING AGENTS FOR BETA CELL MASS OF PANCREAS
胰腺 β 细胞团显像剂
  • 批准号:
    8462596
  • 财政年份:
    2010
  • 资助金额:
    $ 22.93万
  • 项目类别:
In vivo imaging agents targeting Tau aggregates
靶向 Tau 聚集体的体内成像剂
  • 批准号:
    7477147
  • 财政年份:
    2007
  • 资助金额:
    $ 22.93万
  • 项目类别:
In vivo imaging agents targeting Tau aggregates
靶向 Tau 聚集体的体内成像剂
  • 批准号:
    7329991
  • 财政年份:
    2007
  • 资助金额:
    $ 22.93万
  • 项目类别:
New imaging agents for studying gene expression
用于研究基因表达的新型成像剂
  • 批准号:
    7230205
  • 财政年份:
    2006
  • 资助金额:
    $ 22.93万
  • 项目类别:
Imaging agents of norepinephrine transporters
去甲肾上腺素转运蛋白显像剂
  • 批准号:
    6923542
  • 财政年份:
    2005
  • 资助金额:
    $ 22.93万
  • 项目类别:
Imaging agents of norepinephrine transporters
去甲肾上腺素转运蛋白显像剂
  • 批准号:
    7009600
  • 财政年份:
    2005
  • 资助金额:
    $ 22.93万
  • 项目类别:

相似海外基金

CAREER: Elucidating spatial and epigenetic regulation of gene expression during human development using photopatterning and single-cell multiomics
职业:利用光模式和单细胞多组学阐明人类发育过程中基因表达的空间和表观遗传调控
  • 批准号:
    2339849
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Continuing Grant
CAREER: Scalable algorithms for regularized and non-linear genetic models of gene expression
职业:基因表达的正则化和非线性遗传模型的可扩展算法
  • 批准号:
    2336469
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Continuing Grant
CAREER: Epigenetic Regulation of Gene Expression in Engineered Prokaryotes
职业:工程原核生物基因表达的表观遗传调控
  • 批准号:
    2338573
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Continuing Grant
MFB: RNA modifications of frameshifting stimulators: cellular platforms to engineer gene expression by computational mutation predictions and functional experiments
MFB:移码刺激器的RNA修饰:通过计算突变预测和功能实验来设计基因表达的细胞平台
  • 批准号:
    2330628
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Standard Grant
22-BBSRC/NSF-BIO Building synthetic regulatory units to understand the complexity of mammalian gene expression
22-BBSRC/NSF-BIO 构建合成调控单元以了解哺乳动物基因表达的复杂性
  • 批准号:
    BB/Y008898/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Research Grant
How does the chromatin remodeller CHD4 regulate gene expression?
染色质重塑因子 CHD4 如何调节基因表达?
  • 批准号:
    DP240102119
  • 财政年份:
    2024
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Discovery Projects
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 22.93万
  • 项目类别:
Regulation of gene expression by the La and La-related proteins
La 和 La 相关蛋白对基因表达的调节
  • 批准号:
    489704
  • 财政年份:
    2023
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Operating Grants
Investigating the role of SARS-CoV-2 and MERS-CoV transcription regulatory sequence (TRS) in viral gene expression and virulence
研究 SARS-CoV-2 和 MERS-CoV 转录调控序列 (TRS) 在病毒基因表达和毒力中的作用
  • 批准号:
    494272
  • 财政年份:
    2023
  • 资助金额:
    $ 22.93万
  • 项目类别:
    Operating Grants
Application for 2024 CIHR NIF (ECR): Investigating the role of SARS-CoV-2 and MERS-CoV transcription regulatory sequence (TRS) in viral gene expression and virulence
2024 CIHR NIF (ECR) 申请:研究 SARS-CoV-2 和 MERS-CoV 转录调控序列 (TRS) 在病毒基因表达和毒力中的作用
  • 批准号:
    491942
  • 财政年份:
    2023
  • 资助金额:
    $ 22.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了